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Abstract
Chronic alterations in blood flow initiate structural changes in vessel lumen caliber to normalize shear stress. The loss of
endothelial derived nitric oxide synthase (eNOS) in mice promotes abnormal flow dependent vascular remodeling, thus
uncoupling mechanotransduction from adaptive vascular remodeling. However, the mechanisms of how the loss of eNOS
promotes abnormal remodeling are not known. Here we show that abnormal flow-dependent remodeling in eNOS
knockout mice (eNOS (2/2)) is associated with activation of the platelet derived growth factor (PDGF) signaling pathway
leading to the induction of the inhibitor of apoptosis, survivin. Interfering with PDGF signaling or survivin function corrects
the abnormal remodeling seen in eNOS (2/2) mice. Moreover, nitric oxide (NO) negatively regulates PDGF driven survivin
expression and cellular proliferation in cultured vascular smooth muscle cells. Collectively, our data suggests that eNOS
negatively regulates the PDGF-survivin axis to maintain proportional flow-dependent luminal remodeling and vascular
quiescence.
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Introduction
Physiological adaptive remodeling occurs in response to changes
in blood flow [1]. In conduit vessels, increases in blood flow will
increase lumen diameter, while decreases in blood flow will reduce
lumen diameter in order to normalize shear stresses associated
with changes in blood flow. These changes in lumen diameter are
secondary to structural changes triggered by precise regulation of
apoptosis versus proliferation, metalloproteinase activation, coor-
dinated cell migration and organization to change lumen diameter
while keeping wall thickness constant [2,3,4,5].
The molecular mechanisms necessary for adaptive and injury
evoked remodeling are beginning to be appreciated. In a surgical
model, reducing blood flow by 30–40% reduces vessel diameter
without changing wall thickness by an endothelium dependent
mechanism. Denudation of the endothelium prevents flow
mediated inward remodeling demonstrating that the endothelium
senses and transmits the changes in shear stress into biochemical
signals that coordinate structural changes in the vessel wall [4].
Previous work has shown that endothelial nitric oxide synthase
(eNOS) is critical for flow-dependent adaptive remodeling, injury
evoked inward remodeling and ischemia induced shear stress
dependent collateral artery remodeling [6,7,8,9]. Reducing blood
flow in mice deficient in eNOS prevents flow-dependent inward
luminal remodeling and promotes vascular smooth muscle
proliferation leading to an increase in wall thickness [6,10]. Thus,
the loss of eNOS derived nitric oxide (NO) uncouples hemody-
namic changes from adaptive physiological remodeling.
The mechanisms by which the loss of eNOS regulates flow
dependent remodeling are unknown. Here we show that the loss of
eNOS increases platelet derived growth factor (PDGF) expression
with the concomitant induction of the anti-apoptotic protein,
survivin. Interference with either PDGF signaling or antagonizing
the actions of survivin reverses the abnormal remodeling in eNOS
(2/2) mice. In addition, exogenous NO reduces PDGF mediated
proliferation of vascular smooth muscle cells and survivin
induction, in vitro. Thus, eNOS negatively regulates the PDGF-
survivin axis to govern adaptive flow dependent remodeling.
Results
Congenic eNOS (2/2) mice have impaired vascular
remodeling and exhibit media hyperplasia
In our previous study, ligation of the left external carotid artery
(LEC) in F2 generation eNOS (2/2) mice triggered impaired
flow-dependent remodeling in the left common carotid artery (LC)
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31495and paradoxically increased wall thickness via medial cell
proliferation [6]. As seen in Figure 1A, ligation of the LEC for 7
days in C57BL/6J mice reduces lumen diameter by approximately
12% in the LC, without changing wall thickness. In contrast,
ligation of LEC in congenic eNOS (2/2) mice did not change LC
lumen diameters but markedly increased wall thickness (by 33%)
consistent with our previous data in F2 mice showing that eNOS
was critical for proportional remodeling of lumen and wall
thickness. As seen in Figure 1B, the remodeled LC of C57BL/6J
mice is indistinguishable from the contralateral right carotid artery
(RC) or the RC of eNOS (2/2) mice, while the remodeled LC of
eNOS (2/2) mice shows obvious increases in wall thickness.
Chronic decreases in blood flow in LC of eNOS (2/2)
mice induce PDGF-AA/BB and survivin gene expression
The PDGF isoforms (AA and BB) are well characterized, potent
chemotactic and mitogenic growth factors for vascular smooth
muscle cells. To examine if PDGF levels were elevated in
abnormally remodeled eNOS (2/2) mice, we performed
immunohistochemistry and quantitative RT-PCR. Figure 2A
shows greater immunoreactive PDGF-BB protein levels in all
layers of abnormally remodeled LC of eNOS (2/2) mice
compared to RC. The mRNA for PDGF-AA, PDGF-BB,
VEGF-A, FGF2 and TGFb1 is present in RC and remodeled
LC of C57BL/6J detected by quantitative RT-PCR. However, the
expressions of both isoforms of PDGFs, but not other growth fac-
tors were enhanced in abnormally remodeled LC of eNOS (2/2)
mice compared to the paired RC from the same mouse 7 days
post-surgery (Fig. 2B, Fig. S1). These findings suggest that PDGF
may play an important role in abnormal remodeling and medial
proliferation in eNOS (2/2) mice.
Previous data from our group has discovered that PDGF can
induce the expression of the inhibitor of apoptosis, survivin, in
vascular smooth muscle promoting medial cell proliferation after
vascular injury [11]. Thus, we examined survivin expression in
flow-remodeled arteries. Immunoreactive survivin protein (Fig. 2C)
and mRNA levels (Fig. 2D) were elevated in remodeled LC of
eNOS (2/2) mice compared to the contralateral vessel. Low
levels of survivin immunoreactivity and mRNA were found in
C57BL/6J mice or non-remodeled RC of eNOS (2/2) mice.
Given that survivin is an inhibitor of apoptosis, we examined the
apoptosis via TUNEL in remodeled LC of C57Bl/6J and eNOS
(2/2) mice. Apoptosis was detected in the LC in both strains of
mice, but no differences were found in eNOS (2/2) versus
C57BL/6J mice (Fig. S2). These data suggest that the abnormal
LC remodeling in eNOS (2/2) mice was not due to the direct
anti-apoptosis effect of survivin, and perhaps survivin control of
cell cycles contributes to the actions of survivin during remodeling.
Figure 1. Impaired vascular remodeling in congenic eNOS knockout mice. (A) Morphometric analysis showing reductions in lumen
diameter of LC in C57BL/6J mice with no change in wall thickness in response to a remodeling stimulus, yet no change in lumen diameter but an
increase in wall thickness in LC of eNOS (2/2) mice. (B) Hematoxylin and eosin staining showing RC and remodeled LC from a C57BL/6J mouse
(upper panel) and RC and remodeled LC from an eNOS (2/2) mouse (lower panel). Scale bar represents 25 mm. Values are mean 6 SEM; * P,0.05,
** P,0.01 with one way ANOVA with Bonferroni posttest; n=5 for each group of mice.
doi:10.1371/journal.pone.0031495.g001
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pathological remodeling in eNOS knockout mice by
inhibiting vascular smooth muscle cell proliferation and
reducing survivin levels
To examine if upregulation of PDGF contributed to the
abnormal remodeling of eNOS (2/2) mice, we treated eNOS
(2/2) mice (daily from one day before surgery to 7 days post-
surgery) with SU9518, an orally active inhibitor of PDGF receptor
tyrosine kinase, that has been shown to selectively inhibit PDGF
mediated smooth muscle cell migration and proliferation in vivo
[12]. SU9518 competitively inhibits the tyrosine kinase activity of
the PDGF receptors (a and b) and does not influence EGF or FGF
receptor tyrosine kinase signaling (Table 1). Moreover, this
compound has good oral bioavailability and blocks phosphoryla-
tion of the PDGF receptors in carotid arteries isolated from rats
treated in vivo. As shown in Figure 3A, reducing blood flow in
eNOS (2/2) mice did not result in inward remodeling of LC and
triggered an increase in wall thickness (compared to contralateral
RC). However, treatment with SU9518 promoted inward
remodeling of LCs of eNOS (2/2) mice and reduced wall
thickness back to control levels (Fig. 3A and histologically seen in
Fig. 3B). To further test the mechanism of how SU9518 restored
normal remodeling in eNOS (2/2) mice, in vivo cell proliferation
was assessed via BrdU incorporation. Immunohistochemistry of
BrdU showed a marked reduction in BrdU positive cells
throughout endothelium, media and adventitia layer of the vessels
in SU9518 treated LC compare to vehicle treated LC (Fig. 3C)
and the BrdU labeling index showed a significant decreased in the
ratio of proliferating cells/total cells in the vessel wall (Fig. 3D).
Finally, we examined immunoreactive survivin protein levels in
eNOS (2/2) mice treated with SU9518. As seen in Figure 3E,
vehicle treated eNOS (2/2) mice had ample survivin labeling in
abnormally remodeled LC, whereas treatment with SU9518
reduced these levels to background levels. These data demonstrate
that inhibition of PDGF receptor signaling prevents pathological
outward remodeling in eNOS (2/2) mice by decreasing cell
proliferation and survivin levels.
Adenoviral gene delivery of dominant negative,
phosphorylation-defective survivin (T34A) reduces
abnormal remodeling in eNOS knockout mice
To examine if the upregulation of survivin was coincidental or
causal in the abnormal flow-dependent remodeling found in eNOS
(2/2) mice, we used adenoviral (Ad) gene transfer of either Ad-GFP
or Ad-T34A survivin. The T34A mutation in survivin prevents
phosphorylation of the endogenous survivin by the mitotic kinase
Figure 2. PDGF-AA, PDGF-BB and survivin levels are increased in eNOS (2/2) mice in response to remodeling stimulus. (A),
Immunohistochemistry of PDGF-BB protein shows that it is present in adventitia of RC but is increased in all layers of LC post-ligation. Scale bar,
10 mm. (B), Quantitative RT-PCR of PDGF-AA and BB shows there was no change of PDGF mRNA level in wild type mice after LEC ligation. However,
PDGF-AA and BB mRNA are all elevated in ligated LC compare to contralateral RC in eNOS (2/2) mice, 18 s was used as internal control. (C), Survivin
immunohistochemistry shows strong staining throughout whole vessel wall of LC, and there is little or no staining in RC. Scale bar equals to 10 mm.
(D), RT-PCR shows equal expression of survivin mRNA of contralateral RC and ligated LC in wild type mice. However, survivin was upregulated in
ligated LC of eNOS (2/2) mice. 18 s was used as internal control.
doi:10.1371/journal.pone.0031495.g002
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cdc - cyclin B and results in reduced cell growth and apoptosis
[11,13,14]. Viruses were applied to the adventitial side of the vessel
wall immediately after LEC ligation using pluronic gel as a vehicle for
gene delivery and vessel morphometry measured 7 days later. As
document in previous studies, pluronic acid delivery of Ad-GFP
penetrates all layers of the vessel wall, with a gradient from adventitia
to intima [11,15]. As seen in Figure 4A, transduction of LC from
eNOS (2/2) mice with Ad-T34A survivin, but not Ad-GFP,
significantly decreased LC lumen diameter (upper panel), and reduced
the medial thickening (lower panel) comparable to that observed in
WT mice (see Fig. 1). Moreover, the incorporation of BrdU (Fig. 4B)
was reduced in Ad-T34A transduced arteries as quantified as BrdU
positive cells/total cells per section (Fig. 4C), throughout the vessel wall
compared to Ad-GFP transduced vessels. These data suggest that
interference with survivin function can partially correct the impaired
vascular remodeling seen in eNOS (2/2)m i c e .
Figure 3. SU9518 decreases cell proliferation and restore normal remodeling in eNOS (2/2) mice. (A), Lumen diameters (upper panel) of
LC in SU9518 treated eNOS (2/2) mice were reduced in response to a remodeling stimulus but not in LC of vehicle treated eNOS (2/2) mice. Wall
thickness (lower panel) of vehicle treated LC was significantly increased and, SU9518 restored the normal wall remodeling in LC. Values are mean 6
SEM; n=7 for each group of mice; * P,0.05, ** P,0.001 with one way ANOVA with Bonferroni posttest. (B) Representative hematoxylin and eosin
stained LC cross sections of vehicle or SU9518 treated mice. Inward remodeling can be seen in SU9518 treated LC. Scale bar represents 100 mm. (C),
Immunostaining shows BrdU positive cells were detected in all layers of ligated LC in vehicle treated mice (left panel), which blocked by SU9518
treatment as shown on the right panel. Scale bar represents 25 mm. (D), Quantitative BrdU index shows cell proliferation was significantly increased in
vehicle treated LCs of eNOS (2/2) mice, but not in vessels from SU9518 treated eNOS (2/2) mice. (E) PDGF-BB receptor tyrosine kinase inhibitor
decreases immunoreactive survivin levels in LC of eNOS (2/2) mice, compared to vehicle treated eNOS (2/2) mice (left panel). Right panel shows
the quantification of percentage of suvivin positive staining in total vessel area. Values are mean 6 SEM; n=5. * P,0.05, ** P,0.001 with one way
ANOVA with Bonferroni posttest.
doi:10.1371/journal.pone.0031495.g003
Table 1. SU9518 selectively inhibits PDGFR.
Enzyme IC50 (mM) mean±sem (n)
PDGFR ,0.00560.001 (3)
VEGFR2 3.362.6 (6)
FGFR1 2.560.5 (3)
Src 5.867.5 (8)
FAK 40.5 (1)
EGFR .100 (2)
doi:10.1371/journal.pone.0031495.t001
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survivin expression in vitro
Our in vivo data implies that the loss of endogenous eNOS
derived NO permits activation of the PDGF-survivin axis thereby
promoting abnormal vascular smooth muscle cells (VSMC)
proliferation and aberrant vascular remodeling. To directly
examine if NO could regulate PDGF stimulated signaling leading
to the induction of survivin, we initially examined the well-
characterized effects of NO on PDGF driven proliferation of
cultured VSMC. As seen in Figure 5A, PDGF (10 ng/ml) induced
a doubling in cell number after 48 hrs, while the addition of an
NO donor, DETA/NO, dose-dependently reduced PDGF
stimulated VSMC proliferation. Interestingly PDGF induces the
expression of survivin in VSMC (Fig. 5B), an effect dose-
dependently antagonized by the addition of DETA/NO. These
data show that NO can negatively regulate PDGF mediated
survivin induction and support our in vivo findings demonstrating
that the loss of endothelial derived NO promotes this pathway
leading to abnormal vascular remodeling.
Discussion
Here we show that the abnormal vascular remodeling triggered
by the loss of endothelium-derived NO is linked to activation of
the PDGF-survivin pathway. Antagonism of either PDGF receptor
tyrosine kinase activity with SU9815 or endogenous survivin with
adenoviral delivery of a phosphorylation defective mutant of
survivin prevents abnormal carotid arterial remodeling in eNOS
(2/2) mice thereby normalizing flow-dependent luminal remod-
eling to that typically observed in wild-type mice. These studies
support the concept that endogenous endothelium-derived NO
maintains vascular homeostasis by negatively regulating the
PDGF-survivin balance and implies that endothelial dysfunction,
characterized by a loss of NO bioactivity, may promote the early
phases of abnormal vascular remodeling through this mechanism.
This concept is additionally supported by previous data showing
that in two distinct vascular injury models characterized by
endothelial dysfunction, the PDGF-survivin axis regulates medial
thickening [11].
Although it has been appreciated for 20 years that the
endothelium regulates the interface between hemodynamics and
vascular structure, however, the precise molecular mechanisms in
vivo are less well understood. Physiologically, chronic flow
alterations can regulate proportional vascular remodeling either
to increase or decrease lumen diameter. The change in lumen
diameter is necessary to normalize shear stresses brought about by
the flow changes. Using genetically altered mice, eNOS was the
first gene shown to be critical for post-natal, flow-dependent
Figure 4. Ad-T34A survivin transduction blocks cell proliferation and restores normal remodeling in eNOS (2/2) mice. (A) LCs were
transduced with Ad-GFP or Ad-T34A survivin at the time of LEC ligation. Lumen diameter and wall thickness were calculated from 10 sections of
contralateral RC and infected LC of eNOS (2/2) mice. Upper panel shows lumen diameter of Ad-T34A transduced LC was significantly decreased
compared to RC. Ad-T34A transduction also blocks the wall thickening in transduced LC (lower panel). (B), Ad T34A suvivin reduces the number of
BrdU positive cells in LC. (C), BrdU labeling index shows significant increase of BrdU positive cell/total nuclei ratio in Ad-GFP transduced LC compare
to RC in eNOS (2/2) mice. This activation of cell proliferation was blocked by Ad-T34A transduction. Values are mean 6 SEM; * P,0.05, ** P,0.01,
and { P,0.001 with one way ANOVA with Bonferroni posttest; n=5 for each group of mice. Scale bar equals to 25 mm.
doi:10.1371/journal.pone.0031495.g004
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blood flow is a non-inflammatory, hemodynamic remodeling
stimulus different from severe ligation models that stimulate
massive neointima formation and luminal narrowing [16,17].
Upon reducing blood flow in eNOS (2/2) mice, the endothelium
cannot regulate shear stress, thus increasing the proliferation of
vascular smooth muscle, increasing wall thickness to normalize
wall strain. Here, we show that a likely mediator of VSMC
proliferation in the absence of eNOS is PDGF. PDGF levels are
elevated in the absence of eNOS in abnormally remodeled vessels,
but not the contralateral right carotid artery, suggesting that the
inability to regulate shear stress stimulates PDGF synthesis. We
didn’t find much change of other growth factors and their receptor
levels in the remodeled arteries. But, this could be limited by the
specific time point we studied. It is worth doing a time course study
in the future. Moreover, antagonism of PDGF receptors with
SU9518, prevents dysregulated luminal remodeling in eNOS (2/
2) mice, inhibits abnormal VSMC proliferation and corrects the
defect in wall thickness. It can be argued that this inhibitor may
block other growth factor regulated pathways leading to abnormal
remodeling, and we cannot rule this out. However, the presence of
PDGF isoforms and cellular hyperproliferation in abnormally
remodeled vessels from eNOS (2/2) mice, the well-established
actions of NO in antagonizing PDGF induced VSMC prolifera-
tion and migration [18,19,20,21], in conjunction with the data
showing SU9518 blocks BrdU incorporation and abnormal
remodeling in eNOS (2/2) strongly supports PDGF as a stimulus
for abnormal remodeling.
PDGF can activate many signaling pathways that promote
abnormal vascular remodeling. Previous work has shown that
PDGF and angiotensin II can induce survivin gene and protein
expression in VSMC in vitro and in vivo [11,22]. Survivin was
discovered as a novel transcript that was expressed in a variety of
cancer cells and elevated survivin levels are associated with greater
mortality in a variety of human cancers [23,24,25]. It is structurally
and functionally an inhibitor of apoptosis (IAP) due its BIR domains
and functional data showing that survivin expression inhibits
apoptosis in many cell types. Recently, work from several groups
Figure 5. NO donor dose dependently decreases cell number induced by PDGF-BB and blocks survivin expression and in vitro. (A),
Rat SMC were treated or not with PDGF (10 ng/ml), in the absence or presence of the NO donor, DETA/NO (10, 30, and 100 mM) and cell number
quantified after 48 h. (B), NO reduces PDGF induced survivin levels. VSM were treated with PDGF (10 ng/ml) with or withoutt DETA/NONO (10, 30 and
100 mM) and the levels of survivin assessed by Western blotting. DETA/NO dose dependently decreased survivin levels relative to Hsp90 (a protein
loading control). Densitometric values of the ratio of survivin to Hsp90 are shown below the blots. * P,0.05, ** P,0.01 with one way ANOVA with
Bonferroni posttest.
doi:10.1371/journal.pone.0031495.g005
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angiopoietin-1 can also induce survivin expression and reduce the
apoptotic threshold to diverse apoptogens in differentiated, primary
cultures of endothelial cells [26,27,28]. In the context of most cells,
the induction of survivin affords an anti-apoptotic environment
duringG2/Mprogressionofthecell cycle[13].Clearly,antagonism
of survivin function with the phospho-mutant T34A survivin,
increases the apoptotic threshold and reduces cellular proliferation
[11,13,14]. In previous work, we have shown in two distinct models
of vascular injury (associated with elevated levels of PDGF) that
survivinlevels are induced in the expanding neointima. Antagonism
of survivin function using gene delivery of adenovirus encoding
T34A survivin reduced neointimal expansion, BrdU incorporation
and promoted apoptosis [11]. Here, we show that eNOS derived
NO tonically inhibits the PDGF-survivin axis in a non-injurious,
non-inflammtory, flow reducing model of vascular remodeling.
Thus, in the absence of gross endothelial loss and activation of the
coagulation system typically seen in injury paradigms, we show the
loss of eNOS is associated with elevation of the PDGF-survivin
pathway after a flow reducing remodeling stimulus. Neutralization
of either PDGF signaling or survivin function improves the
abnormal remodeling seen in eNOS (2/2) mice. In addition to
this clear evidence in vivo, mechanistically exogenous NO inhibits
PDGF stimulated survivin induction and cellular proliferation in
cultured VSMC. The data showing that a reduction in endogenous
NO derived from endothelium promotes survivin upregulation, and
the exogenous NO to reduces PDGF stimulated survivin levels
extends the observation that high concentrations of NO donor
drugs decrease survivin expression in a variety of cancer cells [29].
Thus, we surmise that the loss of NO bioactivity, either via injury,
secondary to endothelial dysfunction or genetically as in this study,
has the propensity to promote an anti-apoptotic, pro-proliferative
environment conducive to neointima formation or abnormal
remodeling.
Materials and Methods
Left external carotid artery ligation in mice
All animal studies were approved by the institutional animal
care and use committees of Yale University. Eight to ten weeks old
male congenic (backcrossed at least nine generations to the
C57Bl/6J background) eNOS (2/2) or C57BL/6J mice (Jackson
Laboratories, Bar Harbor, ME) were anesthetized with ketamine/
xylazine (79.5 mg/kg ketamine, 9.1 mg/kg; xylazine). Left
external carotid artery ligation and adenoviral gene delivery were
performed essentially as previously described [6,30]. Briefly, the
left external carotid artery was ligated from its origin with 7-0
nylon suture (USSC, Norwalk, CT). In some experiments, eNOS
(2/2) mice were treated with vehicle [1.0% carboxymethylcel-
lulose (CMC) in saline] or SU9518 (3.0%; w/v in CMC vehicle),
an inhbitor of PDGF receptor tyrosine kinase [12] daily by gavage
from one day before surgery to sacrifice day. In additional
experiments, adenoviruses encoding phosphorylation-defective
survivin (Ad-T34A) or green fluorescent protein (Ad-GFP,
3610
8 PFU) were delivered by painting the adventitial side of
the carotid artery with 50 ml of adenovirus/30% Pluronic-127 gel
(Sigma, St. Louis, MO) mixture immediately after ligation [11,31].
All animals were injected with 5-bromo-29deoxyuridine (BrdU)
subcutaneously (25 mg/kg) 3 days before sacrifice daily and
intraperitoneally (30 mg/kg) 12 hr and 24 hr before death to label
proliferating cells. BrdU index was the percentage of BrdU
positive cells of total nuclei in endothelium, media and adventitia.
Carotid arteries were collected at day 7 post-surgery for
morphometric analysis, immunohistochemistry or RNA isolation.
Histology and immunohistochemistry
At sacrifice, perfusion fixed (4% paraformaldehyde in PBS,
PH 7.4) carotid arteries were taken and embedded in O.C.T
(Tissue-Tek, Elkhart, IN). Cryosections (5 mm) of arteries were
obtained for hematoxylin/eosin, elastic staining and immunohis-
tochemistry. For immunohistochemistry, artery sections were
quenched for endogenous peroxidase, blocked by 10% goat serum
and incubated with anti-PDGF BB (R & D systems, Minneapolis,
MN), anti-survivin or anti-BrdU (Pharmingen). Bound primary
antibodies were detected using avidin-biotin-peroxidase (NovaR-
ed
TM peroxidase substrate kit, Vector Laboratories, Burlingame,
CA).
Terminal Deoxynucleotidyl Transferase End Labeling
Apoptotic cells in vascular wall were labeled by TUNEL (TdT-
mediated dUTP nick-end labeling) using the in situ cell death
detection kit TMR-red (Roche Diagnostics) according to the
manufacturer’s protocol. Briefly, dewax paraffin embedded
sections in xylene and rehydrate in graded ethanol series to water.
Heat slides in 10 mM sodium citrate buffer (pH 6.0) at 95–100uC
for 10 minutes and then incubate slides in permeabilisation
solution (0.1% Triton X-100, 0.1% sodium citrate in PBS buffer)
for 2 min on ice. After dialyzed extensively against PBS buffer for
30 min at room temperature, the slides were incubated with 50 ml
TUNEL reaction mixture covered with Para film pieces for
60 min at 37uC in a humidified atmosphere in the dark. To
identify cell types undergoing apoptosis, double staining was
performed by combining TUNEL and immunohistochemistry for
a-SMC actin (smooth muscle cells). TUNEL staining sections were
then viewed using inverted fluorescent microscope and take
photography. Only TUNEL-positive cells that colocalized with
DAPI-stained nuclei were counted as positive and three sections of
each mouse were quantified to detect the apoptotic cell number.
Morphometric analysis
Elastic staining was done on 10 cross-sections from 5 carotid
arteries for each group as previously described. Cross-section
images were collected using a Zeiss microscope and on line CCD
camera (DAGE-MTI, Michigan City, Indiana). The circumfer-
ence of internal elastic lamina (IEL) was measured and artery
diameter was calculated. The distance from IEL to external elastic
lamina (EEL) in four locations of each section was measured by
image analysis software (Scion Image, Frederick, Maryland). The
average was taken as wall thickness.
RT-PCR
Total RNA of single carotid artery was isolated by using
phenol/chloroform. Quantitative RT-PCR was then performed
using 200 ng RNA respectively and primers specific for murine
PDGF-AA, PDGF-BB, PDGFBR, survivin, TGFb1, TGFBR2,
FGF2, FGFR1–4, ANG1, ANG2, TIE1, TIE2, VEGFA,
VEGFR1, VEGFR2, and, 18 s was used as an internal control.
Effects of NO on PDGF-induced smooth muscle
proliferation and survivin expression
A10 rat aortic VSMC were cultured in high glucose Dulbecco’s
modified Eagle’s medium containing 10% (v/v) fetal bovine
serum, penicillin, streptomycin, and L-glutamine. For experiments
VSMC were plated at a density of 5,000 cells/cm
2 into six well cell
culture plates and incubated overnight in normal growth medium.
The next day the cells were washed 2 times with PBS and 2 ml of
serum free DMEM was added to each well. After 24 hours 15 ng/
ml PDGF was added to each well with or without varying
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(2-aminoethyl)-amino]-diazen-1-ium-1,2-diolate). The cells were
incubated for a further 48 hours and the cells were trypsinized and
counted in a Coulter particle counter. To examine survivin
expression, VSMC were plated at approximately 50% confluency
in 10 cm culture dishes and incubated overnight. The next day the
cells were washed 2 times with PBS and 2 ml of serum free
DMEM was added to each well. After 24 hours, PDGF was added
to each well with or without varying concentrations of DETANO/
NOate and incubated for a further 24 hours. The cells were then
washed 2 times with ice cold PBS and lysed on ice in 50 mM Tris
HCL, pH 7.5, 1% Nonidet P-40 (v/v), 10 mM NaF, 1 mM
vanadate, 1 mM pefabloc, 10 mg/ml leupeptin, and lysates were
transferred to microcentrifuge tubes and rotated for 45 min at
4uC. Insoluble material was removed by centrifugation at 12,000 g
for 10 min at 4uC and 20 mg of protein from cell lysates were
analyzed by Western Blot analysis for survivin or hsp90.
Supporting Information
Figure S1 Growth factor and receptor expression in
ligated LC in C57Bl/6J and eNOS (2/2) mice. Quanti-
tative RT-PCR was performed using single remodeled LC and
contralateral RC from C57BL/6J and eNOS (2/2) mice. There
was no change of mRNA level of multiple growth factors and their
receptors in LC of wild type mice 7 days after LEC ligation.
However, there was a trend of induction (2-fold but not significant
compared to WT) of FGF2, FGFR2, TGFbR2, Ang2 and Tie1
expression in LC compared to RC in eNOS (2/2) mice. N=3,
one way ANOVA was used for statistical analysis.
(TIF)
Figure S2 Loss of eNOS does not alter cell apoptosis in
response to flow alteration in vivo. (A) Representative
images of TUNEL stained remodeled LC from C57Bl/6J and
eNOS (2/2) mice 7 days after LEC ligation. TUNEL label in
red, SMA staining in green. (B) Quantification of percentage of
TUNEL positive cells in total vascular wall cells. N=3 animal,
student T-test was used for statistical analysis.
(TIF)
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